Conmed Corp
NYSE:CNMD

Watchlist Manager
Conmed Corp Logo
Conmed Corp
NYSE:CNMD
Watchlist
Price: 38.515 USD 0.46%
Market Cap: $1.2B

P/OCF

7.1
Current
44%
Cheaper
vs 3-y average of 12.7

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
7.1
=
Market Cap
$1.4B
/
Operating Cash Flow
$170.7m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
7.1
=
Market Cap
$1.4B
/
Operating Cash Flow
$170.7m

Valuation Scenarios

Conmed Corp is trading below its 3-year average

If P/OCF returns to its 3-Year Average (12.7), the stock would be worth $69 (79% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+368%
Average Upside
165%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 7.1 $38.52
0%
3-Year Average 12.7 $69
+79%
5-Year Average 33.2 $180.15
+368%
Industry Average 16.1 $87.24
+127%
Country Average 13.3 $72.42
+88%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
US
Conmed Corp
NYSE:CNMD
1.2B USD 7.1 25.7
US
Intuitive Surgical Inc
NASDAQ:ISRG
171.2B USD 55.6 59
US
Abbott Laboratories
NYSE:ABT
158.3B USD 16.8 25.6
US
Stryker Corp
NYSE:SYK
125.3B USD 24.9 38.7
IE
Medtronic PLC
NYSE:MDT
106.9B USD 14.6 23.1
US
Boston Scientific Corp
NYSE:BSX
92B USD 19.9 25.3
US
Edwards Lifesciences Corp
NYSE:EW
48.9B USD 30.7 44.7
DE
Siemens Healthineers AG
XETRA:SHL
40B EUR 13.2 19
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.1B USD 38.9 43.4
US
Becton Dickinson and Co
NYSE:BDX
43.3B USD 12.7 24.5
US
Resmed Inc
NYSE:RMD
32B USD 16.9 21.8

Market Distribution

Lower than 79% of companies in the United States of America
Percentile
21st
Based on 9 488 companies
21st percentile
7.1
Low
0 — 8.8
Typical Range
8.8 — 20.1
High
20.1 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 8.8
Median 13.3
70th Percentile 20.1
Max 3 188 432.5

Conmed Corp
Glance View

Conmed Corporation, founded in the small city of Utica, New York, has carved a niche for itself in the competitive world of medical technology. The company, which began its journey in the mid-1970s, has evolved into a global player by specializing in a variety of surgical and patient care products. At its core, Conmed thrives on its deep expertise in the design and manufacturing of surgical instruments used predominantly in minimally invasive procedures. These include sophisticated medical devices for orthopedic, laparoscopic, robotic, and general surgeries. Conmed’s strategic focus has always been on innovation, driven by a commitment to enhance the surgeon's ability to provide superior patient care, which is evident in their continuous research and development efforts aimed at creating more efficient and effective tools for medical professionals. The revenue streams for Conmed are as diversified as their product offerings. By selling advanced surgical equipment and medical products to hospitals, surgical centers, and outpatient facilities worldwide, Conmed positions itself as a critical supplier in the healthcare industry. A significant portion of their income is derived from the repeat sales of disposable items and replacement parts required for these high-tech devices. This creates a continuous cycle of revenue through both initial capital sales and recurring sales of consumables, quintessential for sustaining robust financial stability. Furthermore, the company's growth strategy has been marked by strategic acquisitions, allowing it to broaden its array of products and enter new markets, thereby ensuring its continued prominence and adaptability in the ever-evolving landscape of healthcare technology.

CNMD Intrinsic Value
84.44 USD
Undervaluation 54%
Intrinsic Value
Price $38.515
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett